Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by langostaon Sep 18, 2018 11:53am
139 Views
Post# 28639199

RE:Starting to wonder..

RE:Starting to wonder..When the OSC gives you a slap on the wrist that's not good.

I doubt this PP is even close to being filled.

The following is still hanging over our heads. Until there is a clean ou on the management issue this problem will remain.

  • Establish a Disclosure Committee to oversee and approve its disclosure;
  •  
  • Cause each of its directors and officers to complete a corporate governance course on disclosure issues satisfactory to OSC Staff, the cost of which course will not exceed $2,500;
  •  
  • Ensure that, for a period of five years, Mr. DumoulinWhite complies with certain restrictions regarding his ability to engage in specified disclosure, investor relations and financing related activities, as further detailed below; and
  •  
  • Cancel 4,000,000 stock options previously granted to Mr. Dumoulin-White for future services (which have exercise prices of $0.50, of which 1,000,000 expire on July 11, 2019 and 3,000,000 expire on May 28, 2020) (“Future Service Options”).

Under the terms of the Agreement, Mr. DumoulinWhite will:

  • Immediately resign any position that he holds as a director or officer of an issuer (including the Company);
  •  
  • Not become or act as a director or officer of a reporting issuer or any related entity for a period of five years;
  •  
  • Not become or act as a director or officer of any non-reporting issuer (other than a related entity of a reporting issuer with respect to which the five year prohibition applies) for a period of three years; 
  •  
  • Pay an administrative penalty in an amount equal to $250,000, less the costs of the Consultant (not to exceed $150,000) paid by him;
  •  
  • For a period of five years, (i) not engage in specified disclosure activities; (ii) not engage, directly or indirectly, in any significant investor relations activities; and (iii) ensure that any of his activities for the raising of financing by, or the solicitation of investments in, the Company be supervised by its Chief Executive Officer or a member of the Disclosure Committee;
  •  
  • Before engaging in any activities described immediately above, engage in a full day of one-on-one training with the Consultant regarding disclosure issues;
  •  
  • Before becoming a director or officer of an issuer, complete an education program, satisfactory to OSC Staff, relating to the obligations of directors and officers;
  •  
  • Not dispose of any of his securities of the Company until the day following the date the first management’s discussion and analysis is required to be filed by the Company following the completion of 12 months of the Consultant’s engagement; and
  •  
  • Surrender for cancellation his Future Service Options.


Bullboard Posts